Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jun 13;17(6):777.
doi: 10.3390/pharmaceutics17060777.

Revolutionizing Diabetes Management Through Nanotechnology-Driven Smart Systems

Affiliations
Review

Revolutionizing Diabetes Management Through Nanotechnology-Driven Smart Systems

Aayush Kaushal et al. Pharmaceutics. .

Abstract

Diabetes is a global health challenge, and while current treatments offer relief, they often fall short in achieving optimal control and long-term outcomes. Nanotechnology offers a groundbreaking approach to diabetes management by leveraging materials at the nanoscale to improve drug delivery, glucose monitoring, and therapeutic precision. Early advancements focused on enhancing insulin delivery through smart nanosystems such as tiny capsules that gradually release insulin, helping prevent dangerous drops in blood sugar. Simultaneously, the development of nanosensors has revolutionised glucose monitoring, offering real-time, continuous data that empowers individuals to manage their condition more effectively. Beyond insulin delivery and monitoring, nanotechnology enables targeted drug delivery systems that allow therapeutic agents to reach specific tissues, boosting efficacy while minimising side effects. Tools like microneedles, carbon nanomaterials, and quantum dots have made treatment less invasive and more patient-friendly. The integration of artificial intelligence (AI) with nanotechnology marks a new frontier in personalised care. AI algorithms can analyse individual patient data to adjust insulin doses and predict glucose fluctuations, paving the way for more responsive, customised treatment plans. As these technologies advance, safety remains a key concern. Rigorous research is underway to ensure the biocompatibility and long-term safety of these novel materials. The future of diabetes care lies in the convergence of nanotechnology and AI, offering personalised, data-driven strategies that address the limitations of conventional approaches. This review explores current progress, persistent challenges, and the transformative potential of nanotechnology in reshaping diabetes diagnosis and treatment and improving patient quality of life.

Keywords: AI in diabetes management; carbon nanomaterials; continuous glucose monitoring (CGM); diabetes mellitus; diabetic wound healing; drug delivery systems; electrochemical biosensors; glucose biosensors; glucose monitoring; insulin delivery; microneedles; nanofibers; nanomedicine; nanotechnology; non-invasive monitoring; polymeric nanoparticles; quantum dots (QDs); smart nanocarriers; wearable biosensors.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Mechanism and classification of diabetes based on insulin production and response.
Figure 2
Figure 2
Overview of pharmaceutical nanosystems in diabetes, illustrating nanocarriers for targeted drug delivery and nanosensors for glucose monitoring and diagnosis.
Figure 3
Figure 3
Schematic showing variations in nanoparticle properties such as surface charge, size, shape, and structure affecting their functionality.
Figure 4
Figure 4
Applications of nanofibers in biomedical and therapeutic domains.
Figure 5
Figure 5
Synergistic nanotech framework for advanced diabetes management.

Similar articles

References

    1. Mukhtar Y., Galalain A., Yunusa U. A Modern Overview on Diabetes Mellitus: A Chronic Endocrine Disorder. Eur. J. Biol. 2020;5:1–14. doi: 10.47672/ejb.409. - DOI
    1. Katsarou A., Gudbjörnsdottir S., Rawshani A., Dabelea D., Bonifacio E., Anderson B.J., Jacobsen L.M., Schatz D.A., Lernmark Å. Type 1 diabetes mellitus. Nat. Rev. Dis. Primers. 2017;3:17016. doi: 10.1038/nrdp.2017.16. - DOI - PubMed
    1. DeFronzo R.A., Ferrannini E., Groop L., Henry R.R., Herman W.H., Holst J.J., Hu F.B., Kahn C.R., Raz I., Shulman G.I., et al. Type 2 diabetes mellitus. Nat. Rev. Dis. Primers. 2015;1:15019. doi: 10.1038/nrdp.2015.19. - DOI - PubMed
    1. Alam S., Hasan M.K., Neaz S., Hussain N., Hossain M.F., Rahman T. Diabetes Mellitus: Insights from Epidemiology, Biochemistry, Risk Factors, Diagnosis, Complications and Comprehensive Management. Diabetology. 2021;2:36–50. doi: 10.3390/diabetology2020004. - DOI
    1. Forouhi N.G., Wareham N.J. Epidemiology of diabetes. Medicine. 2022;50:638–643. doi: 10.1016/j.mpmed.2022.07.005. - DOI - PMC - PubMed

LinkOut - more resources